COVID-19. COVID disease
Conditions
Interventions
Intervention 1: Intervention group: patients using spirulina platensis supplement plus standard treatment of Covid-19. Intervention 2: Control group: patients receiving standard Covid-19 treatment alo
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Male and female patients, age =18. The patient is stable in condition and does not need resuscitation. Signed informed consent form. Definitive/clinical diagnosis of coronavirus. The same treatment protocol (coronavirus) in both groups. oxygen saturation =94%.
Exclusion criteria
Exclusion criteria: Pregnancy or lactation. Any history of drug allergy. Active, clinically significant chronic illness or human immunodeficiency virus disease. Significant organ dysfunctions such as renal failure, liver dysfunction, CHF, or serious and unstable cardiac condition. Underlying conditions that can affect patients' ability to provide adequate data. Inability or refusal to sign the informed consent. Any concurrent diseases or conditions which delay wound healing (cancer, vasculitis, immunosuppressive disorders, etc.) Treatment with corticosteroids, Treatment with blood thinners(Warfarin), immunosuppressants, radiotherapy, or chemotherapy. Receiving any investigational drug within 30 days prior to screening. Abnormal liver enzymes and total bilirubin > 1.5 times of normal upper limit. Specific and rare diseases such as people with HIV who are not receiving antiretroviral treatment, multiple sclerosis, SLE, rheumatoid arthritis, and PKU. Observation of clinical signs not previously seen in patients with coronavirus and unusual complaints from patients. Severe nausea after taking medication that does not improve with routine supportive treatment is considered as an exclusion criterion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease severity. Timepoint: The first day, the third day, the fifth day, and the seventh day are the periods of measuring the variables of our study. Method of measurement: Disease severity is measured by the relevant variables: Lymphocyte count, Alanine transaminase, Aspartate transaminase, White Blood Cells, Erythrocyte sedimentation rate, C-Reactive Protein, Hemoglobin, Creatinine, D-Dimer, ferritin, Platelet, Lactate Dehydrogenase, Prothrombin Time, Oxygen saturation and Patient body temperature. Cytokines and chemokines levels, including IL-10, IL-6, IP-10, IFN?, TNFa, CCL2, and CCL3, are also measured by enzyme-linked immunosorbent assay (ELISA). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohamadAli ZaheriBirgani
Pasture Institute of Iran
Outcome results
None listed